Hematologic Malignancy
Mature B-Cell Neoplasm
CI-CAN-00003258Explore in graph →
HematologicNon-malignant1,787 active trials44 approved drugs119 evidence items
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00003258Explore in graph →
Clinical trials
6,664 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07096778 | Inobrodib, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma(DOMMINO-1) | recruiting | Phase 2 | 100 | CellCentric Ltd.INDUSTRY | 2 | Sep 21, 2026 | clinicaltrials |
| NCT07802717 | A Phase 1 Dose-escalation and Expansion Study of In Vivo BCMA-CAR T Cell Therapy (VV169) in Patients With Relapsed or Refractory Multiple Myeloma | recruiting | Phase 1 | 40 | Vyriad, Inc.INDUSTRY | 1 | Sep 21, 2026 | clinicaltrials |
| NCT07210047 | Study of HuL001 in Relapsed/Refractory Multiple Myeloma Patients | recruiting | Phase 1 / Phase 2 | 21 | HuniLife Biotechnology, Inc.INDUSTRY | 1 | Sep 18, 2026 | clinicaltrials |
| NCT07382739 | A Phase 2 Study of Radiotherapy-induced Immune Priming to Enhance Elranatamab (Elra) in Relapsed Refractory Multiple Myeloma (RRMM) With Extramedullary Disease (EMD) and Paramedullary Disease (PMD) "PRIME-EMD-PMD" | recruiting | Phase 2 | 34 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT07422610 | Pharmacokinetics and Safety Study of Pelabresib in Patients With Advanced Malignancies and Hepatic Impairment | recruiting | Phase 1 | 24 | Novartis PharmaceuticalsINDUSTRY | 4 | Sep 18, 2026 | clinicaltrials |
| NCT07652905 | CM336 Plus Isa-VR in Newly Diagnosed Primary Plasma Cell Leukemia(CAREMM-011) | recruiting | Phase 2 | 24 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT04879043 | Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma | recruiting | Phase 1 / Phase 2 | 78 | Heidelberg Pharma AGINDUSTRY | 5 | Sep 17, 2026 | clinicaltrials |
| NCT04910568 | A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma(CAMMA 1) | recruiting | Phase 1 | 186 | Genentech, Inc.INDUSTRY | 13 | Sep 17, 2026 | clinicaltrials |
| NCT06395103 | Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01) | recruiting | Phase 1 / Phase 2 | 90 | Merck Sharp & Dohme LLCINDUSTRY | 23 | Sep 17, 2026 | clinicaltrials |
| NCT07221500 | A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201) | recruiting | Phase 2 | 100 | Nurix Therapeutics, Inc.INDUSTRY | 5 | Sep 17, 2026 | clinicaltrials |
| NCT07341191 | Sonrotoclax Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma Planned for Standard of Care CAR-T Cell Therapy | recruiting | Phase 2 | 40 | Canadian Cancer Trials GroupNETWORK | 1 | Sep 17, 2026 | clinicaltrials |
| NCT07585760 | CM336 Plus Isatuximab for Newly Diagnosed Multiple Myeloma With Renal Impairment(CAREMM-012) | recruiting | Phase 2 | 26 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT07623798 | A Study in Participants With Relapsed or Refractory Multiple Myeloma for IBI3003 | recruiting | Phase 3 | 255 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 1 | Sep 17, 2026 | clinicaltrials |
| NCT07760454 | A Clinical Study of CT0596 CAR-T in Relapsed/Refractory Multiple Myeloma | recruiting | Phase 1 / Phase 2 | 68 | UCARsgen Biotech LimitedOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT07825064 | Cevostamab in Combination With Pomalidomide and Dexamethasone After BCMA- Targeting CAR T-Cell Therapy in Participants With Previously Treated Multiple Myeloma | recruiting | Phase 2 | 45 | Hoffmann-La RocheINDUSTRY | 1 | Sep 17, 2026 | clinicaltrials |
| NCT00900198 | Collection of Tissue Samples for Cancer Research | recruiting | — | 5,000 | National Cancer Institute (NCI)NIH | 2 | Sep 16, 2026 | clinicaltrials |
| NCT04002947 | Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma | recruiting | Phase 2 | 132 | National Cancer Institute (NCI)NIH | 1 | Sep 16, 2026 | clinicaltrials |
| NCT04322383 | Binimetinib for People With Relapsed/Refractory BRAF Wild Type Hairy Cell Leukemia and Variant | recruiting | Phase 2 | 40 | National Cancer Institute (NCI)NIH | 1 | Sep 16, 2026 | clinicaltrials |
| NCT04815356 | Phase I Study of Anti-CD22 Chimeric Receptor T Cells in Patients With Relapsed/Refractory Hairy Cell Leukemia and Variant | recruiting | Phase 1 | 27 | National Cancer Institute (NCI)NIH | 1 | Sep 16, 2026 | clinicaltrials |
| NCT05283993 | A Cohort Study of Plasma Cell Disorders (PCDs) in PKUFH | recruiting | — | 2,000 | Peking University First HospitalOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT05757219 | Itacitinib Pre-modulation in DLBCL Receiving CAR T Cell Therapy | recruiting | Phase 2 | 27 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT05892393 | Imaging Study of [89Zr]DFO-YS5 for Detecting CD46 Positive Malignancy in Multiple Myeloma | recruiting | Phase 1 | 20 | Robert Flavell, MD, PhDOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT06345027 | Chimeric Antigen Receptor Treatment Targeting CD70 (SEVENTY)(CASEY) | recruiting | Phase 1 | 78 | Baylor College of MedicineOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT06735664 | Zanubrutinib in Combination With Odronextamab for the Treatment of Patients With Richter's Transformation | recruiting | Phase 1 | 23 | City of Hope Medical CenterOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT06832865 | ELISA in Relapsed/Refractory MM | recruiting | Phase 2 | 30 | Massachusetts General HospitalOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT07181941 | Response-Based Dose Reduction of Linvoseltamab in the Treatment of Relapsed, Refractory, or Triple-Class Relapsed/Refractory Multiple Myeloma | recruiting | Phase 1 / Phase 2 | 30 | Fred Hutchinson Cancer CenterOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT07215494 | A Clinical Study on Minimal Residual Disease in Patients With Systemic Light Chain Amyloidosis | recruiting | N/A | 50 | Peking University First HospitalOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT07343934 | huCART19-IL18-eDHFR Cells in Relapsed/Refractory Follicular Lymphoma | recruiting | Phase 1 | 6 | University of PennsylvaniaOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT04094311 | Study of Out of Specification for Tisagenlecleucel | recruiting | Phase 3 | 200 | Novartis PharmaceuticalsINDUSTRY | 2 | Sep 15, 2026 | clinicaltrials |
| NCT06182774 | Fixed Duration vs Continuous Anti-CD38 Antibody Therapy Among Transplant Ineligible Older Adults With Newly-Diagnosed Multiple Myeloma | recruiting | Phase 3 | 570 | Canadian Cancer Trials GroupNETWORK | 1 | Sep 15, 2026 | clinicaltrials |
| NCT06615479 | A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2) | recruiting | Phase 3 | 440 | Juno Therapeutics, Inc., a Bristol-Myers Squibb CompanyINDUSTRY | 31 | Sep 15, 2026 | clinicaltrials |
| NCT06976476 | Study of IgPro20 to Prevent Infection in People With Multiple Myeloma and Hypogammaglobulinemia | recruiting | Phase 2 | 100 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07620275 | Safety and Efficacy of KSVCBD Injection in Multiple Myeloma Expressing CD19 and/or BCMA | recruiting | Phase 1 | 9 | Chinese PLA General HospitalOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT04314752 | Development of a Research Infrastructure for Understanding and Addressing Multiple Myeloma Disparities(MEDULLA) | recruiting | — | 4,000 | University of California, DavisOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT06297226 | Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma(QUINTESSENTIAL) | recruiting | Phase 2 | 230 | Juno Therapeutics, Inc., a Bristol-Myers Squibb CompanyINDUSTRY | 4 | Sep 14, 2026 | clinicaltrials |
| NCT06514508 | Mobilization of Stem Cells With Motixafortide (BL-8040) in Combination With G-CSF in Multiple Myeloma Patients | recruiting | Phase 3 | 60 | Guangzhou Gloria Biosciences Co., Ltd.INDUSTRY | 1 | Sep 14, 2026 | clinicaltrials |
| NCT06827860 | Subcutaneous Talquetamab in Elderly Patients With Multiple Myeloma in Early Relapse | recruiting | Phase 2 | 23 | Larysa SanchezOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT06953960 | A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM) | recruiting | Phase 1 / Phase 2 | 325 | AbbVieINDUSTRY | 12 | Sep 14, 2026 | clinicaltrials |
| NCT07085728 | Testing the Investigational Agent Combination of Daratumumab, Bortezomib, and Dexamethasone Compared to the Usual Treatment of Cyclophosphamide, Bortezomib, and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients With Kidney Failure | recruiting | Phase 2 | 74 | Eastern Cooperative Oncology GroupNETWORK | 1 | Sep 14, 2026 | clinicaltrials |
| NCT07558915 | A Study to Evaluate RO7851624 in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) | recruiting | Phase 1 | 160 | Genentech, Inc.INDUSTRY | 1 | Sep 14, 2026 | clinicaltrials |
| NCT07817641 | Proton Therapy for Mediastinal Lymphoma (PROMLY)(PROMLY) | recruiting | N/A | 139 | Rigshospitalet, DenmarkOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT05934084 | Lifestyles Implemented-Survivorship Care Plan In Lymphoma Survivors | recruiting | N/A | 552 | Fondazione Italiana Linfomi - ETSOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT06049290 | A Clinical Trial of LBL-034 in Patients With Relapsed Refractory Multiple Myeloma | recruiting | Phase 1 / Phase 2 | 342 | Nanjing Leads Biolabs Co.,LtdINDUSTRY | 1 | Sep 11, 2026 | clinicaltrials |
| NCT06091254 | A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma(OLYMPIA-1) | recruiting | Phase 3 | 822 | Regeneron PharmaceuticalsINDUSTRY | 19 | Sep 11, 2026 | clinicaltrials |
| NCT06517017 | Use of Isatuximab, Dexamethasone and Lenalidomide in a Go-Slow Fashion for Ultra-Frail Patients With Multiple Myeloma(UltraFrailMM) | recruiting | Phase 2 | 40 | University of UtahOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT06526793 | Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL(SOUNDTRACK-B) | recruiting | Phase 2 | 270 | AstraZenecaINDUSTRY | 16 | Sep 11, 2026 | clinicaltrials |
| NCT06830031 | Clinical Study of C402-CD19-CAR Treatment in Subjects With Relapsed or Refractory B-cell Lymphoma(C402) | recruiting | Phase 1 | 18 | Shanghai Exuma Biotechnology Ltd.INDUSTRY | 1 | Sep 11, 2026 | clinicaltrials |
| NCT07061951 | Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic Leukemia | recruiting | Phase 2 | 20 | National Cancer Institute (NCI)NIH | 1 | Sep 11, 2026 | clinicaltrials |
| NCT07194980 | Nemtabrutinib and Lisocabtagene Maraleucel for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | recruiting | Phase 2 | 20 | Fred Hutchinson Cancer CenterOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT07455851 | A Trial to Study if REGN17372 in Combination With Linvoseltamab is Tolerable for Adult Participants With Relapsed/Refractory Multiple Myeloma | recruiting | Phase 1 / Phase 2 | 150 | Regeneron PharmaceuticalsINDUSTRY | 2 | Sep 11, 2026 | clinicaltrials |
Data updated 5 days agoSource updated Sep 21, 2026source: clinicaltrials